Lenacapavir: Discussing the Latest Research at  

HIV.gov hosted a discussion on the findings of the PURPOSE 1 study where the safety and efficacy of lenacapavir as long-acting injectable PrEP among cisgender women. Brian Minalga facilitated the talk with Dr. Carl Dieffenbach from NIAID, Tori Cooper from HRC, and Dr. Jono Mermin from CDC.
Subscribe to HIV.gov for daily updates from AIDS 2024: cloud.connect....